Robert van Nostrand

OSI Pharmaceuticals, Inc. manufactured and develope dpharmaceutical drugs. The company was founded in 1983 and was headquartered in Farmingdale, NY.

Achillion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of oral small molecule complement system inhibitors. Its pipeline includes Danicopan and ACH-5228. The company was founded on August 17, 1998 and is headquartered in Blue Bell, PA.

Applied Genetics, Inc. Dermatics develops and markets pharmaceutical drugs, skincare ingredients and prestige products. It develops array of cosmetic ingredients to use in skin care products. The company has focused on ingredients for skin protection from environmental damage. The firm also has a topical pharmaceutical product in clinical testing called Dimericine for cancer-prone skin. Applied Genetics was founded by Daniel B Yarosh and Karen Yarosh in May 1985 and is headquartered in Freeport, NY.

Aureon Biosciences, Inc. designs and develops prognostic tests. The company’s prognostic tests include Prostate Px, which assists physicians as they counsel patients on the range of possible treatment options, as well as the patient’s probability of disease recurrence, disease progression and Post-Op Px, a prognostic test to provide patients and their physicians with information about treatment options. The company was founded by Robert H. Singer, Charles M. Cohen, Jonathan Edelson, Olivier Saidi and Carlos Cordón-Cardó in 2001 and is headquartered in Yonkers, NY.

The Company is a blank check company. It is formed to acquire one or more domestic or foreign operating business in the healthcare industry through merger, capital stock exchange, asset acquisition or other similar business combination. The Company is in the development stage. On February 5, 2008, the Company entered into an Agreement and Plan of Merger with Dynogen Pharmaceuticals, Inc and its acting representatives.

Enumeral Biomedical Holdings, Inc. is a biopharmaceutical company, which engages in the business of discovering and developing novel antibody immunotherapies for the treatment of cancer and other diseases. It also focuses on the development of a pipeline of next generation monoclonal antibody drugs targeting established and novel immuno-modulatory receptors. The company was founded by Barry C. Buckland, John J. Rydzewski, and Arthur H. Tinkelenberg on December 11, 2009 and is headquartered in Arlington, MA.